Kenichi Chikamori

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki et al. · Journal of Thoracic Oncology · 2017 · 175 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami et al. · Journal of Thoracic Oncology · 2015 · 104 citations

Medicine, Oncology, Pharmacology +12

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

Kōichi Goto, Makoto Nishio, Noboru Yamamoto et al. · Lung Cancer · 2013 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17

Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase IIα Regulates Enzymatic Activity and Drug Sensitivity

Kenichi Chikamori, Dale Grabowski, Michael Kinter et al. · Journal of Biological Chemistry · 2003 · 62 citations · Full text

Medicine, Molecular Biology, Oncology +12

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients

Makoto Nishio, Haruhiro Saito, Kōichi Goto et al. · Cancer Science · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacotherapy +15